| HOME >> BIOLOGY >> TECHNOLOGY |
SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that FierceBiotech has named iPierian as one of 2010's Fierce 15, designating it as one of the most promising biotech companies in the industry. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position.
"iPierian's scientific advisory board is a Who's Who of stem cell and top disease experts," said John Carroll, editor of FierceBiotech. "By applying cutting-edge work on cell reprogramming and differentiation, iPierian promises to pioneer iPS technology that can offer a radically improved approach to identifying and developing new therapies for some of the world's toughest disease targets, where there are only poor in vivo and in vitro models available."
"Following our 2009 'Fierce 15' award, we are delighted that the editors of FierceBiotech selected iPierian for this recognition again in 2010," said Michael C. Venuti, PhD, CEO of iPierian. "With our focus on industrializing and applying this transformative technology to drug discovery and development, we look forward to advancing our proprietary therapeutic programs, and to entering collaborative arrangements with pharmaceutical companies and foundations over the coming year."
About iPierian
iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease mod
'/>"/>
| SOURCE iPierian, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
2. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
3. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
6. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
9. Thomson Reuters Names the Worlds Hottest Researchers
10. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
11. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |